دورية أكاديمية
Precision medicine in aggressive thyroid cancer: Moving beyond multitargeted tyrosine kinase inhibitors.
| العنوان: | Precision medicine in aggressive thyroid cancer: Moving beyond multitargeted tyrosine kinase inhibitors. |
|---|---|
| المؤلفون: | Mahmood U; Dana-Farber Cancer Institute, Boston, Massachusetts., Lorch JH; Dana-Farber Cancer Institute, Boston, Massachusetts. |
| المصدر: | Cancer cytopathology [Cancer Cytopathol] 2022 Jan; Vol. 130 (1), pp. 8-11. Date of Electronic Publication: 2021 Nov 08. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 101499453 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1934-6638 (Electronic) Linking ISSN: 1934662X NLM ISO Abbreviation: Cancer Cytopathol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Hoboken, NJ : Wiley-Blackwell |
| مواضيع طبية MeSH: | Antineoplastic Agents*/therapeutic use , Thyroid Neoplasms*/drug therapy , Thyroid Neoplasms*/genetics, Humans ; Precision Medicine ; Protein Kinase Inhibitors/therapeutic use |
| References: | Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014;384:319-328. Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372:621-630. Brose MS, Cabanillas ME, Cohen EEW, et al. Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;17:1272-1282. Subbiah V, Kreitman RJ, Wainberg ZA, et al. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J Clin Oncol. 2018;36:7-13. Shah MH, Wei L, Wirth LJ, et al. Results of randomized phase II trial of dabrafenib versus dabrafenib plus trametinib in BRAF-mutated papillary thyroid carcinoma. J Clin Oncol. 2017;35(suppl):6022. Wirth LJ, Sherman E, Robinson B, et al. Efficacy of selpercatinib in RET-altered thyroid cancers. N Engl J Med. 2020;383:825-835. Blueprint Medicines Corporation. GAVRETO™ (pralsetinib) [package insert]. US Food and Drug Administration. Revised January 2019. Accessed May 20, 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214701s000lbl.pdf. Cabanillas ME, Drilon A, Farago AF, et al. Larotrectinib treatment of advanced TRK fusion thyroid cancer. Ann Oncol. 2020;31:S1086. Rolfo CD, De Braud FG, Doebele RC, et al. Efficacy and safety of entrectinib in patients (pts) with NTRK-fusion positive (NTRK-fp) solid tumors: an updated integrated analysis. J Clin Oncol. 2020;38(suppl):3605. Hanna GJ, Busaidy NL, Chau NG, et al. Genomic correlates of response to everolimus in aggressive radioiodine-refractory thyroid cancer: a phase II study. Clin Cancer Res. 2018;24:1546-1553. Huang FW, Feng FY. A tumor-agnostic NTRK (TRK) inhibitor. Cell. 2019;177:8. Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378:731-739. Lim SM, Chang H, Yoon MJ, et al. A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes. Ann Oncol. 2013;24:3089-3094. Schneider TC, de Wit D, Links TP, et al. Beneficial effects of the mTOR inhibitor everolimus in patients with advanced medullary thyroid carcinoma: subgroup results of a phase II trial. Int J Endocrinol. 2015;2015:348124. Schneider TC, de Wit D, Links TP, et al. Everolimus in patients with advanced follicular-derived thyroid cancer: results of a phase II clinical trial. J Clin Endocrinol Metab. 2017;102:698-707. Harris EJ, Hanna GJ, Chau N, et al. Everolimus in anaplastic thyroid cancer: a case series. Front Oncol. 2019;9:106. Wagle N, Grabiner BC, Van Allen EM, et al. Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med. 2014;371:1426-1433. |
| المشرفين على المادة: | 0 (Antineoplastic Agents) 0 (Protein Kinase Inhibitors) |
| تواريخ الأحداث: | Date Created: 20211108 Date Completed: 20220418 Latest Revision: 20220418 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1002/cncy.22516 |
| PMID: | 34748686 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1934-6638 |
|---|---|
| DOI: | 10.1002/cncy.22516 |